Does Cosentyx Affect Fertility in Women?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows no evidence of impairing fertility in women. Animal studies in rats and cynomolgus monkeys at doses up to 24 times the human exposure found no effects on female fertility, including estrus cycles, implantation, or early embryonic development.[1][2] Human data is limited, but no fertility issues have been reported in clinical trials or post-marketing surveillance.
What Do Clinical Studies and Real-World Data Say?
Pregnancy exposure registries and observational studies, including those from the European Medicines Agency (EMA) and FDA, report no signals of fertility impairment in women using Cosentyx. Over 2,000 pregnancies exposed to secukinumab have been tracked, with live birth rates similar to the general population (around 70-80%) and no fertility-related adverse outcomes noted.[1][3] Women planning pregnancy are advised to discuss with their doctor, as the drug's half-life is about 27 days, suggesting a 4-5 month washout before conception.[2]
Can Men or Partners Use Cosentyx During Conception?
No fertility impact in male rats or monkeys was observed, even at high doses. Human semen parameters remain unaffected in studies of men on Cosentyx.[1][2] Partners of women trying to conceive face no restrictions based on available data.
Pregnancy and Breastfeeding Considerations
Cosentyx crosses the placenta (most in third trimester) but shows no increased malformation risk (1.5% vs. 3-5% background rate).[3] It's rated Pregnancy Category B (animal data reassuring, limited human data). Limited milk transfer occurs, but oral absorption by infants is low; breastfeeding is generally considered compatible after weighing benefits.[1][2]
What Do Guidelines Recommend for Women Trying to Conceive?
The American College of Rheumatology suggests continuing Cosentyx until pregnancy confirmation if benefits outweigh risks, then stopping. European guidelines align, with no fertility-specific warnings.[3] Always consult a rheumatologist or dermatologist for personalized advice.
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: MotherToBaby Fact Sheet on Secukinumab